LBH589 Inhibits Glioblastoma Growth and Angiogenesis Through Suppression of HIF-1α Expression

• Published in: Journal of neuropathology and experimental neurology 2017-12, Vol.76 (12), p.1000-1007
• Main Authors: Yao, Zhi-Gang, Li, Wen-Huan, Hua, Fang, Cheng, Hong-Xia, Zhao, Miao-Qing, Sun, Xi-Chao, Qin, Ye-Jun, Li, Jia-Mei
• Format: Article
• Language: English
• Subjects: Animals; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glioblastoma - drug therapy; Glioblastoma - pathology; Histone Deacetylase Inhibitors - pharmacology; Histone Deacetylase Inhibitors - therapeutic use; Humans; Hydroxamic Acids - pharmacology; Hydroxamic Acids - therapeutic use; Hypoxia-Inducible Factor 1, alpha Subunit - antagonists & inhibitors; Hypoxia-Inducible Factor 1, alpha Subunit - biosynthesis; Indoles - pharmacology; Indoles - therapeutic use; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - pathology; Tumor Burden - drug effects; Tumor Burden - physiology; Xenograft Model Antitumor Assays - methods
• ISSN: 0022-3069; 1554-6578
• DOI: 10.1093/jnen/nlx088

Abstract Glioblastoma (GBM) is an angiogenic malignancy with a highly unfavorable prognosis. Angiogenesis in GBM represents an adaptation to a hypoxic microenvironment and is correlated with tumor growth, invasion, clinical recurrence, and lethality. LBH589 (also called panobinostat) is a histone deacetylase (HDAC) inhibitor with potent antitumor activity. In the current study, we investigated the mechanism and effects of LBH589 on GBM growth and hypoxia-induced angiogenesis in vitro and in vivo. To determine the antitumor and angiogenesis activity and mechanism of LBH589, we used cell proliferations in vitro and GBM xenografts in vivo. To clarify mechanisms of LBH589 on angiogenesis, HDAC assay, RT-PCR, Western blot, and co-immunoprecipitation assays were performed. We found LBH589 displayed significant antitumor effects on GBM as demonstrated by inhibited cell proliferation, slower tumor growth, and decreased microvessel density of subcutaneous xenografts. These actions of LBH589 resulted from the disruption of heat shock protein 90/HDAC6 complex, increased HIF-1α instability and degradation, and decreased VEGF expression. Our results indicate the potential antiangiogenic activity of LBH589 in human GBM and provide some preclinical data to warrant further exploration of HDAC inhibitors for the treatment of advanced glioma. Moreover, our study supports the role of HDAC inhibitors as a therapeutic strategy to target tumor angiogenesis.